MedTrace Logo

Safety and Pharmacokinetics of ELB353 in Healthy Men

NCT00977886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-11-16

No results posted yet for this study

Summary

The purpose of this trial is to study the safety and tolerability of repeated oral doses of ELB353, to evaluate the plasma levels of ELB353 and to study their effect on substances mediating inflammation.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Placebo

Oral, 10 days

DRUG

ELB353

Oral, 10 days

Sponsors & Collaborators

  • Biotie Therapies Corp.

    lead INDUSTRY

Principal Investigators

  • Antero Kallio, MD · Biotie Therapies Corp.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977886 on ClinicalTrials.gov